Avatrombopag dosage instructions

Drug name: Avatrombopag

Common name: Avatrombopag

Drug class: Thrombopoietin receptor agonist (TPO-Ragonist)

Indications: For the treatment of chronic immune thrombocytopenia (ITP) in adults

Usage and dosage:

1.Initial dose:

The initial dose is 20 milligrams (mg) once daily.

The dose may be gradually adjusted based on the patient's platelet count and treatment response, with the maximum dose not exceeding80mg once daily.

2.Dose adjustment:

After treatment is initiated, adjust the dose based on the patient's platelet count at least one week apart.

If the platelet count is below the target range (usually 50 to 150 × 10^9/L), the dose may be increased; if the platelet count is above the target range, the dose may be reduced or treatment may be suspended.

3.Dose Reduction and Interruption:

If the patient reaches the target platelet count and it remains stable, consider tapering the dose or suspending treatment.

During dose tapering or treatment interruption, patients' platelet counts should be monitored regularly to ensure that they remain within a stable range.

4.Guidance on dosage adjustment:

Dose adjustments should be based on the individual patient's condition and clinical manifestations.

The patient's platelet count, bleeding risk, and other clinical factors should be considered when adjusting dosage.

Medication:

1.Oral administration: Avatrombopag is an oral drug and should be swallowed whole with sufficient water. It can be taken before or after meals, but the taking time should be consistent every day to ensure the stability of the therapeutic effect.

2.Interaction between drugs and food: Avatrombopag can be taken with food, but it is not recommended to take it with calcium-containing foods to reduce the absorption of the drug.

Precautions for use in special populations:

1.Elderly patients: For elderly patients, special dose adjustment is usually not required, but it should be used with caution based on the patient's liver and kidney function.

2.Patients with impaired hepatic function: For patients with mild to moderate hepatic impairment, dose adjustment is generally not required. For patients with severe hepatic impairment, the dose should be reduced and liver function indicators should be monitored regularly.

3.Patients with impaired renal function: For patients with impaired renal function, dose adjustment is generally not required, but renal function indicators should be closely monitored.

4.Children and adolescent patients:

The safety and effectiveness of avatrombopag in children and adolescents have not been established and its use in this population is not recommended.

Adverse reactions:

Common adverse reactions of avatrombopag include but are not limited to:

1.Headache: Probably one of the most common adverse reactions.

2.Weakness: It may appear at the beginning of treatment, but it usually reduces gradually.

3.Nausea and Diarrhea: Mild gastrointestinal discomfort may occur.

4.Abnormal liver function: Including elevated transaminase, etc.

5.Other adverse reactions: Such as rash, eye pain, etc.

Medication discontinuation and emergency treatment: If the patient experiences serious adverse reactions or allergic reactions, he should stop taking the medication immediately and seek medical treatment immediately.

Storage conditions: Avatrombopag should be stored in a dry, cool place away from children.

Drug Interactions: While taking avatrombopag, doctors should be informed of other medications the patient is taking to avoid possible drug interactions.

Notes:

1.While patients are taking avatrombopag, their platelet count should be monitored regularly to ensure that it is maintained at an appropriate level.

2.Patients should follow the doctor’s instructions and recommendations and use the drug in strict accordance with the prescribed dosage and usage.

3.If you experience any discomfort or adverse reactions while using avatrombopag, you should report it to your doctor in time and seek help.